# Monarch Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/monarch-biosciences

- Industry: Biotechnology
- Headquarters: Los Angeles, US
- Website: www.monarch-bio.com
- Total disclosed funding: $1M
- Latest round: Seed (Apr 6, 2020)
- Investors on record: 1

## About

Monarch Biosciences Inc. is a company focused on the commercialization of advanced medical device and biotechnology products, utilizing innovative Thin Film Nitinol technology to enhance patient outcomes in healthcare.Monarch Biosciences Inc. specializes in developing medical devices that leverage Thin Film Nitinol technology. The company is based in Los Angeles, US. It was founded by Colin Kealey, who has a history in the healthcare sector. In April 2020, Monarch raised USD 1 million in Seed funding led by Checkmate Capital, marking a significant milestone in its funding journey. The company has conducted one deal to date, with its most recent funding round occurring on April 6, 2020.Monarch Biosciences specializes in the commercialization of advanced medical device and biotechnology products that leverage Thin Film Nitinol technology. This innovative approach enables the development of devices that exhibit superior performance characteristics, including enhanced flexibility, strength, and durability, making them suitable for a range of medical applications. The company focuses on addressing critical healthcare challenges, such as improving patient outcomes in minimally invasive procedures. Their client base includes hospitals, surgical centers, and healthcare providers across North America and Europe, who utilize these products to deliver treatment options to patients. Monarch's offerings cater to diverse medical specialties, thus expanding their reach in the global healthcare market.Monarch Biosciences generates revenue predominantly through direct sales of its flagship medical devices to healthcare institutions. The company employs a B2B transaction structure, where products are sold directly to hospitals and clinics, ensuring that these institutions have access to the latest in medical technology. Revenue streams are supported by long-term partnerships and agreements with healthcare providers, enabling integrated solutions that enhance clinical outcomes. Pricing structures for their advanced devices reflect the value delivered in terms of improved patient care and operational efficiency, although specific pricing details remain undisclosed. The company’s commitment to innovation positions it strongly within the biotechnology sector, reinforcing its potential for sustainable revenue generation.Monarch Biosciences is working on the development of new medical devices that utilize advanced materials and technologies, aiming for launches in the upcoming years. The company plans to expand into European markets, targeting specific regions with high healthcare demands by 2022. The recent Seed funding of USD 1 million raised in April 2020 will support these initiatives, facilitating product development and market entry strategies.

## Funding rounds

- Seed, Apr 6, 2020, $1M — Checkmate Capital

## Investors

- Checkmate Capital (https://capitalatlas.ai/funds/checkmate-capital) — Seed